Combination regimens and immunologic mechanisms to enhance the efficacy of cemiplimab for cutaneous squamous cell carcinoma

Expert Rev Anticancer Ther. 2022 Feb;22(2):237-238. doi: 10.1080/14737140.2022.2020652. Epub 2021 Dec 30.

Authors

Hannah L Hanania¹, Daniel J Lewis²

Affiliations

¹ School of Medicine, Baylor College of Medicine, Houston, TX, USA.
² Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

PMID: 34918605
DOI: 10.1080/14737140.2022.2020652

No abstract available

Keywords: Immunotherapy; Toll-like receptor; anti-PD-1; cemiplimab; cutaneous squamous cell carcinoma.

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents, Immunological* / pharmacology
Antineoplastic Agents, Immunological* / therapeutic use
Carcinoma, Squamous Cell* / drug therapy
Carcinoma, Squamous Cell* / pathology
Humans
Skin Neoplasms* / drug therapy
Skin Neoplasms* / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
cemiplimab